AAN: Tolebrutinib Slows Disability in Nonrelapsing Secondary Progressive MS
WEDNESDAY, April 9, 2025 (HealthDay News) — Tolebrutinib, a brain-penetrant and bioactive...
Read More
Search Physician’s Weekly
Search for articles, editorials, meeting coverage, podcasts, and more
Showing 12 results for 'tolebrutinib'
Paramagnetic Rim Lesions Predict Effectiveness of Tolebrutinib
Results of a post hoc analysis of 3 phase 3 trials of tolebrutinib suggest that PRLs are associated with an increased risk for disability accumulation in MS.
Read More
Tolebrutinib Slows Disability Worsening in Relapsing MS
Patients with multiple sclerosis found that their symptoms did not worsen with intake of tolebrutinib, in the GEMINI 1 and 2 studies.
Read More
Pharmacological Comparison of Tolebrutinib with Other BTK Inhibitor Candidates for MS Treatment
Tolebrutinib, a covalent inhibitor of Bruton tyrosine kinase (BTK), has been specifically...
Read More
MRI Results of Tolebrutinib Long-Term Safety Extension Study in Relapsing MS
Tolebrutinib, a potent inhibitor of Bruton tyrosine kinase that can cross the blood-brain barrier,...
Read More
Tolebrutinib Reduces New Active Brain Lesions in Relapsing MS
BTK inhibitor also shows promise in slowly evolving lesions Tolebrutinib, an investigational...
Read More
American Academy of Neurology, April 5-9
The annual meeting of the American Academy of Neurology was held this year from April 5...
Read More
Comorbidity Burden Tied to Risk for Adverse Events in MS
A higher comorbidity burden was associated with an increased rate of AESI and early discontinuation among patients with MS in clinical trials of DMTs.
Read More
Pre-Relapse Immune Signature Implicates EBV Reactivation in MS Relapse
Researchers identified a monocyte/dendritic cell response to EBV reactivation in B cells as one of the earliest events in developing MS relapse.
Read MoreAdvertisement
Immunomodulatory Potential of Ketogenic Diet in MS Confirmed
Research found that following a ketogenic diet for 6 months can reprogram immune cell metabolism and promote anti-inflammatory phenotypes in patients with MS.
Read MoreTargeting CNS cells Key to Abrogate MS Progression
Prof. Tony Traboulsee talks to Physician’s Weekly about his study of tolebrutinib Presented at the...
Read More
ACTRIMS-ECTRIMS: The Potential of Brain-Penetrant BTK Inhibitors
This year, MSVirtual2020 (ACTRIMS/ECTRIMS) congress will feature new data relating to tolebrutinib...
Read More